Background. Frailty is a syndrome of decreased physiologic reserve that results from compromise of multiple physiologic systems including cardiovascular system. We aimed to determine the association between the frail phenotype and cardiac abnormalities in liver transplant (LT) candidates through evaluation of transthoracic echocardiography (TTE) indices. Methods. Included were consecutive outpatients listed for LT who underwent a frailty assessment from January 1, 2014, to June 30, 2016 (using the Liver Frailty Index) and a 2-dimensional/Doppler TTE examination. Patients were categorized as robust, intermediate frail, or frail by the Liver Frailty Index based on scores of less than 3.2, between 3.2 and 4.5, or 4.5 or greater. Linear regression assessed associations between the Liver Frailty Index and TTE indices. Results. Of 335 patients, 19% were robust, 65% intermediate frail, and 16% frail. TTE indices of left atrial (LA) dilatation differed significantly by frailty status: median LA dimension (P = 0.03), LA volume index (LAVI mL/m 2 ; P < 0.001) and %LAVI > 34 mL/m 2 (P = 0.001). In linear regression adjusted for age, sex, hypertension, and diabetes, the Liver Frailty Index was positively associated with LA dimension (coeff, 0.20; 95% confidence interval [CI], 0.07-0.34), LAVI mL/m 2 (coeff, 0.01; 95% CI, 0.005-0.02), ejection fraction (coeff, 1.59; 95% CI, 0.32-2.85), and pulmonary artery systolic pressure (coeff, 0.01; 95% CI, 0.003-0.02), and negatively associated with LV hypertrophy (coeff, −0.22; 95% CI, −0.37 to −0.06). Conclusions. In LT candidates, frailty is associated with cardiac structural and functional changes, independent of known risk factors. Our study provides evidence to support that measures of frailty in cirrhotic patients encompass abnormalities of the cardiovascular system and may inform assessments of cardiovascular reserve in this population.
and neurologic. However, little is known about whether these same systems contribute to frailty in patients with cirrhosis, who are, in general, younger than the geriatric population.
Of particular interest is the role that cardiovascular dysfunction plays in the frail phenotype in patients with cirrhosis. In contrast to hypertensive and ischemic heart disease classically seen in older adults without known liver disease, cardiovascular abnormalities in cirrhotic patients are characterized by hyperdynamic circulation with high cardiac output, decreased arterial pressure, and total peripheral resistance. 4 Beginning in the late 1980s, occasional reports of unexpected deaths due to heart failure after liver transplantation, 5 transjugular intrahepatic portosystemic shunt (TIPS) insertion, 6 and surgical portocaval shunts 7 led to increased attention to cardiac dysfunction related to cirrhosis. Subsequently, the literature has established that the presence of cirrhosis per se is associated with cardiovascular abnormalities that worsen overall prognosis and perioperative outcomes, regardless of the cause of liver disease. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In older adults without liver disease, cardiac abnormalities identified on transthoracic echocardiogram (TTE) have been associated with the frail phenotype. [23] [24] [25] Whether these cardiovascular abnormalities associated with cirrhosis result in worsening physiologic reserve, as measured by objective assessments of frailty, remains largely unknown. Therefore, we aimed to determine the association of the frail phenotype with cardiac structure and function in patients with cirrhosis through evaluation of TTE indices. We hypothesized that frailty would be associated with echocardiographic characteristics in patients with cirrhosis.
MATERIALS AND METHODS

Study Design
We performed a cross-sectional study at a single, highvolume liver transplant center with patients enrolled in the Functional Assessment in Liver Transplantation (FrAILT) Study from January 1, 2014, to June 30, 2016 , who had a 2-dimensional (2D) and Doppler TTE within 365 days of their frailty assessment. The TTE indices we considered as the key parameters of this study were left chamber measurements (left atrial [LA] and left ventricle [LV] dimensions, volume and mass), ejection fraction (EF), and the descriptive statement of Doppler evidence of diastolic dysfunction (DD).
Study Population
The FrAILT study enrolls consecutive adult patients with cirrhosis who are actively listed for liver transplantation and are seen as outpatients at the University of California, San Francisco (UCSF) Liver Transplant Clinics. 26 Patients were eligible for enrollment in the FrAILT study if they had a Model for End-Stage Liver Disease (MELD) score of 12 or higher or if they were 60 years or older. Patients were excluded if they had severe hepatic encephalopathy, as defined by the time to complete a Numbers Connection Test longer than 120 seconds, given concerns over their ability to fully cooperate with the frailty testing.
For this specific study, the eligibility criteria were as follows: (a) enrollment in the FrAILT study from January 1, 2014, to June 30, 2016, and (b) receipt of a standardized 2D and Doppler TTE within 365 days of the frailty assessment. and coronary artery disease (CAD); and (iv) frailty parameters, were collected on all patients from the patient's electronic health record by study personnel at the time of the frailty assessment. Patients were classified as having hypertension or diabetes if this was listed in their medical history or they were prescribed medication(s) to manage these diseases. History of CAD was determined from medical chart. Ascites was ascertained from the physical examination or discussion of ascites in the management plan.
Frailty Assessment
Frailty was assessed using 3 simple, performance-based tests: dominant hand grip strength, timed chair stands, and balance. The Liver Frailty Index, an index to objectively measure frailty specific to patients with cirrhosis, was calculated from the scores of these 3 tests (http://liverfrailtyindex.ucsf.edu/). Patients with a Liver Frailty Index in the bottom 20%ile (<3.2) of the FrAILT study cohort were classified as "robust" and those with a Liver Frailty Index in the top 80%ile (≥4.5) of the FrAILT study cohort were classified as "frail," based on our prior published study. 26 
TTE Measurements
All patients included in this study underwent cardiovascular assessment by a standard 2D and Doppler TTE as part of their pretransplant protocol either within our center or outside institutions. In total, TTE reports were collected from 64 centers; 28% were performed at our own institution. We only analyzed data from TTE reports that contained the basic information recommended by the American Society for Echocardiography. 27 For patients with more than 1 eligible TTE, we analyzed the TTE closest to the date of the frailty assessment.
We evaluated the following TTE indices: (i) measurements of cardiac left chambers morphology (LA and LV dimensions, volume and mass), (ii) measurements of cardiac systolic function (EF), (iii) measurements of cardiac DD (statement of doppler evidence of DD), and (iv) Estimated pulmonary artery systolic pressure (PASP). These specific TTE indices were selected because they have previously been associated with adverse cardiac-related outcomes in patients with cirrhosis. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Regarding their assessment methods, left chamber measurements were collected and indexed to body surface area as recommended by the American Society for Echocardiography and the European Association of Cardiovascular Imaging, to allow comparison among individuals with different body sizes. 28 If LA volume index (LAVI) or left ventricular mass index (LVMI) measurements were not provided, we calculated them using the height and weight included in the TTE report and the area-length method and the 2D echocardiography necropsy-validated formula, 22 respectively, through an online calculator provided by the Canadian Society of Echocardiography (http://csecho.ca/mdmath). Systolic function was classified according to the EF, as "normal" if EF in the range of 53% to 73%, "depressed" if EF is less than 53% or hyperdynamic if EF is greater than 73%. 28 Parameters of DD were collected including primary measurements of mitral inflow (peak early filling [E wave] and late diastolic filling [A wave] velocities and E/A ratio), tissue doppler annular early (e') and late (a') diastolic velocities and E/e', an additional time ratio. 29 To aid the assessment of LV DD, additional morphologic and functional information were also collected including LAVI of 34 mL/m 2 or greater, presence of LV hypertrophy (defined as a finding in the TTE report or a LVMI > 115 g/m 2 for men and > 95 g/m 2 for women), and PASP estimated (derived from Bernoulli equation with the tricuspid regurgitation jet. 29 According to guidelines in force during the study period for identifying DD in subjects with normal EF, the mitral inflow E velocity to tissue Doppler e' (E/e') ratio should be calculated, whereas in patients with depressed EF, the transmitral inflow pattern by itself (E/A ratio) is usually sufficient for diagnosis. 28 Therefore, DD was defined as diagnosis of "Doppler evidence of DD" included in the TTE report and classified according to the degree of DD provided by the cardiologist, in 4 different filling patterns ("normal," "mild or impaired relaxation," "moderate or pseudonormal," "severe or reversible/ fixed restrictive," or "findings inconclusive to estimate" in the case of discordance with available variables).
Statistical Analysis
We reported baseline and TTE characteristics using categories of frailty (by cutoffs of the Liver Frailty Index) to facilitate interpretation of characteristics that are generally associated with the frail phenotype. Continuous distributions were summarized as medians (interquartile range [IQR]), and discrete data were summarized as frequencies (percentages). Differences in baseline characteristics and TTE indices by frailty status were compared using χ 2 or Kruskal-Wallis tests for categorical and continuous variables, respectively.
To precisely quantify the association between frailty and TTE indices and to control for confounding, we performed multivariate linear regression models using the Liver Frailty Index as a continuous variable, adjusted for age, sex, diabetes, and hypertension, because these factors are known to be independently associated with cardiac structural abnormalities on TTE. 23, 25 The primary TTE indices of interest were left chamber measurements, EF, and the descriptive statement of Doppler evidence of DD.
A cutoff P value less than 0.05 was used to determine statistical significance. STATA v14 (College Station, Texas) was used for all statistical analyses.
This manuscript adheres to the Strengthening The Reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. 30 
RESULTS
Participants
Of the 433 patients enrolled in the FrAILT Study during the study period, 59 (14%) were excluded because the TTE provided did not include the measurements and descriptive items recommended by guidelines, 27 and 39 (9%) were excluded because they did not have a TTE within 365 days of their frailty assessment ( Figure 1 ).
Baseline Characteristics of the Cohort
Baseline characteristics of the 335 patients included in this cohort are shown in Table 1A , column A. Thirty-four percent were women, and median age was 60 years (IQR, 19-74 years). Forty-eight percent had chronic HCV infection, and 38% had HCC. Median MELDNa score at testing was 18 (IQR, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and Child Pugh score was 8 (IQR, 6-9). Ascites was present in 25% of the cohort, and 16% had moderate hepatic encephalopathy. Hypertension, diabetes, and CAD were present in 44%, 23%, and 5%, respectively. The median number of days between the frailty assessment and TTE assessment was 119 days (IQR, 51-186).
Baseline Measurements of Frailty
The median Liver Frailty Index score was 3.82 (IQR, 3.35-4.28). A total of 53 (16%) subjects were classified as "frail" (Liver Frailty Index score, ≥4. and 73%) in 87% of patients with a median EF of 65% (IQR, 63-70%). The majority (62%) had no Doppler evidence of DD although 41% had an LAVI of 34 mL/m 2 or greater, 31% had LV hypertrophy, and the median PASP was 28 mm Hg (IQR, 23-33).
Demographic Characteristics Associated With Frailty
Baseline characteristics among robust versus intermediate frail and frail subjects are shown in Table 1A , columns B, C, and D, respectively. The 3 groups were similar with respect to age, sex, body size, cardiovascular risk factors, rates of dialysis, and days between frailty and TTE assessments (P > 0.05). Frail patients had higher MELD and MELDNa scores, rates of mild/moderate and severe ascites, and rates of moderate hepatic encephalopathy (P < 0.05). As shown in Tables 1A and 1B , patients who were classified as frail also had a lower proportion of HCC-and HCV-related cirrhosis but a higher proportion of alcohol and NASH cirrhosis (P < 0.05).
TTE Findings Associated With Frailty
TTE findings in the robust, intermediate and frail groups are described in Table 2 , columns B, C, and D, respectively. TTE indices of LA dilation (LA dimension and volume) showed no significant differences between the 3 categories of the Liver Frailty index. Likewise, these 3 groups had no significant differences regarding TTE indices of systolic function (EF) and DD ("doppler evidence of DD" and "proportion of LAVI ≥ 34 mL/m 2 "). When subjects were divided into stages of systolic and DD, there were still no significant differences between frail, intermediate and robust patients.
In linear regression models adjusted for age, sex, hypertension, and diabetes, the Liver Frailty Index 95% CI, −0.37 to −0.06). There were no significant associations between the Liver Frailty Index and LVMI or Doppler evidence of DD (Table 3) .
DISCUSSION
Frailty has recently emerged as a potent predictor of mortality in patients with cirrhosis. 2, 3, 26 However, little is known of the major contributors to the frail phenotype in this population. Based on reports from the geriatric literature, we hypothesized that the frail phenotype would be associated with cardiac structural and functional abnormalities. Indeed, we observed that, in our cohort of 335 patients with cirrhosis, patients who were frail had higher rates of LA enlargement, EF, PASP, and lower proportion of LV hypertrophy compared with nonfrail patients, independent of known cardiac risk factors including age, sex, diabetes, and hypertension. Notably, the strongest association between TTE indices and the frail phenotype was with higher LA volume and PASP. This is of particular interest given the previously described association between higher LAVI and DD in cirrhotic patients. 14 In addition, in the field of cardiology, high LAVI, as defined by LAVI of 34 mL/m 2 or greater, is an independent predictor of clinically relevant outcomes, including heart failure, ischemic stroke, and death. 21, 27 Similarly, elevated PASP is independently associated with cardiac events in patients with and without heart failure. [31] [32] [33] Whether these findings contribute to the increased risk of death among frail cirrhotic patients should be further investigated in a larger study with longer-term follow-up in this population.
The precise pathophysiology underlying the observed associations between cardiac structural changes and frailty is unknown, but we offer the following potential explanations based on what has been described in the literature from the fields of hepatology, cardiology, and geriatrics. First, LA enlargement reflects the cumulative effects of elevated filling pressures over time. 29 In patients with cirrhosis, this may occur as an adaptive response to the hyperdynamic circulation and the trophic effects caused by continuous activation of several neurohumoral systems such as the sympathetic nervous system or the renin-angiotensin-aldosterone system. That cirrhotic patients with DD display elevated levels of atrial natriuretic peptide provides evidence of this association. 34 Second, the increased EF and lower proportion of LV hypertrophy observed in frail cirrhotic patients may serve as the cardiac manifestation of the cumulative effect of portal hypertension. It is also possible that general muscle wasting contributed to the lower proportion of LV hypertrophy that we observed in the frail patients in our cohort.
There are similarities and differences in our findings in cirrhotic patients as compared with those in older adults without cirrhosis. In both older adults (without cirrhosis) and cirrhotic patients, frailty is associated with LA enlargement and PASP but, unlike patients with end-stage liver disease, adults 65 years or older had a lower EF and an increased LVMI. [23] [24] [25] Particularly, the lower EF seen in frail noncirrhotic patients suggests that decreased cardiologic reserve may contribute to the frail phenotype in an elderly subject without liver disease more than it does in a younger frail cirrhotic. On the other hand, the increased LVMI observed in frail geriatric patients denotes an opposite direction in cardiac remodeling in subjects with cirrhosis than in older adults with normal hepatic synthetic function. Our data suggest a hallmark of TTE findings which might differentiate frail cirrhotic patients from both nonfrail cirrhotic patients and frail noncirrhotic patients.
We acknowledge the following limitations to our study. First, the TTE examinations included in this study represent TTEs performed at multiple different institutions, because liver transplant candidates often complete their cardiac evaluations at their local facility, rather than at our transplant center. However, these were the same TTE reports that were used for clinical decision making at our transplant center, so the analyses that we performed using these data could be generalizable to real-life clinical practice. Second, the timeframe between TTE and frailty assessment ranged anywhere from 0 to 362 days; the extent of frailty may have changed during the interim between the TTE and the actual measurement of frailty. Nevertheless, we did not observe any significant differences in the median number of days between TTE and frailty measurement by frailty category, so we do not believe that this contributed substantial bias to our results. Third, we were unable to adjust for a broad range of cardiopulmonary conditions in our cohort (eg, congestive heart failure, atrial fibrillation)-although we did adjust for hypertension-but given that all of the patients included in our cohort were approved for liver transplantation at our institution, we believe that the prevalence of clinically significant cardiopulmonary disease would be low and unlikely to substantially change our analyses. Similarly, we did not collect information on portopulmonary hypertension, but the prevalence of portopulmonary hypertension at UCSF is very low (<5%), supported by a median PASP was 28 mm Hg in our cohort. Lastly, the decision of not adjusting by severity of liver disease (MELD and Child-Pugh scores, albumin, sodium, platelets, and ascites) was deliberate because the Liver Frailty Index captures by itself portal hypertension status and systemic hemodynamics.
Despite these limitations, our study is the first to evaluate the association of cardiac abnormalities with frailty in patients with end-stage liver disease. Moreover, it provides provocative evidence to support that measures of frailty in cirrhotic patients encompass, among other systems, abnormalities of the cardiovascular system and can be used to objectively measure underlying cardiovascular reserve in this population. Whether these TTE abnormalities associated with frailty in cirrhotic patients have the potential to predict pretransplant, peritransplant, and posttransplant cardiovascular events warrants further investigation. Given the progressive aging and the increasing cardiovascular comorbidities of liver transplant candidates as well as the cardiovascular abnormalities intrinsically associated with cirrhosis, we advocate for the integration of objective frailty measures, such as the Liver Frailty Index, into the routine clinical assessments of cirrhotic patients on the liver transplant waitlist. TTE indices associated with the Liver Frailty Index (as a continuous variable) using linear regression models, adjusted for age, sex, hypertension and diabetes mellitus" 
